Kura Oncology, Inc. (KURA) Stock Price & Analysis
Kura Oncology, Inc. (KURA) rose 2.92% to USD 8.81 as of June 10, 2026 at 03:43 UTC, according to Nexqual real-time market data.
KURA last closed at USD 8.56; the session ranged USD 8.62–9.02 on volume of 2,000,470 shares. Market capitalization is $782.10M, with a 52-week range of USD 5.45–12.49 (NMS). Source: Nexqual, June 10, 2026 at 03:43 UTC.
Key Statistics (as of June 10, 2026 at 03:43 UTC)
| Price | USD 8.81 |
|---|---|
| Change | ▲ 2.92% (up) |
| Previous Close | USD 8.56 |
| Open | USD 8.78 |
| Day Range | USD 8.62 – 9.02 |
| 52-Week Range | USD 5.45 – 12.49 |
| Volume | 2,000,470 shares |
| Market Cap | $782.10M |
| Exchange | NMS |
Technical Analysis (KURA)
Nexqual's technical model rates KURA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:43 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.05 (neutral) |
| vs SMA50 | Below (USD 9.22) |
| MACD | -0.16 (negative) |
Analyst Ratings (KURA)
Wall Street analysts rate KURA "Strong Buy" based on 12 analysts, with a mean price target of USD 31.17 (range USD 15–76), per Nexqual as of June 10, 2026 at 03:43 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 31.17 |
| High Target | USD 76 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 14 / 1 / 0 |
Earnings (KURA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.91 |
| Revenue Estimate | $19.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.92 vs est -0.49 ▼ miss |
| 2025-09-30 | USD -0.85 vs est -0.68 ▼ miss |
| 2025-06-30 | USD -0.75 vs est -0.37 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
Financials & Fundamentals (KURA)
| Total Revenue | $71.64M |
|---|---|
| Revenue Growth (YoY) | +29.50% |
| Gross Margin | -263.88% |
| Operating Margin | -431.51% |
| Profit Margin | +0.00% |
| ROE | -124.74% |
| Debt / Equity | 22.5 |
| Current Ratio | 6.15 |
| Total Cash | $580.82M |
| Total Debt | $24.27M |
| Free Cash Flow | $-129.83M |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
Financial Health Score (KURA)
Nexqual rates Kura Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:43 UTC.
| Growth | Strong — Revenue +25% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $581M cash vs $24M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$130M, burning cash |
| Efficiency | Critical — ROE -125%, ROA -28.4% |
Ownership (KURA)
| Insider Ownership | +1.43% |
|---|---|
| Institutional Ownership | +96.38% |
| Shares Outstanding | 88.77M |
| Float | 70.33M |
| Short % of Float | +15.72% |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
Leadership (KURA)
Kura Oncology, Inc. is led by Troy Edward Wilson (age 56), Chairman, CEO & President, per Nexqual as of June 10, 2026 at 03:43 UTC.
| Chairman, CEO & President | Troy Edward Wilson (age 56) |
|---|---|
| Chief Operating Officer | Kathleen Ford (age 78) |
| Senior Vice President of Finance & Accounting | Thomas Doyle (age 54) |
| Chief Scientific Officer | Francis J. Burrows (age 63) |
| Senior Vice President of Investor Relations & Corporate Affairs | Greg Mann |
Major Backers & Investors (KURA)
Notable institutional backers of Kura Oncology, Inc. include Suvretta Capital Management, LLC, BVF Inc., Armistice Capital, LLC, according to Nexqual as of June 10, 2026 at 03:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.66% |
| BVF Inc. | 9.51% |
| Armistice Capital, LLC | 4.21% |
| Prosight Management, Lp | 3.78% |
| Deep Track Capital, Lp | 2.98% |
| AQR Capital Management, LLC | 2.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.02% |
| Vanguard Group | 8.43% |
| State Street | 8.26% |
| Geode Capital | 2.29% |
Source: Nexqual, June 10, 2026 at 03:43 UTC.
From Kura Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals, Inc. | USD 17.69 | ▲ 2.02% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
| KALV | KalVista Pharmaceuticals, Inc. | USD 26.99 | ▲ 0.15% |
| RGNX | REGENXBIO Inc. | USD 6.34 | ▲ 4.28% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:43 UTC. This page is informational and not investment advice.